Canagliflozin Patent Expiration
Canagliflozin is used for the treatment of type 2 diabetes mellitus and reduction of cardiovascular and kidney-related risks. It was first introduced by Janssen Pharmaceuticals Inc
Canagliflozin Patents
Given below is the list of patents protecting Canagliflozin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Invokana | US10617668 | Pharmaceutical formulations | May 11, 2031 | Janssen Pharms |
| Invokana | US7943582 | Crystalline form of 1-(β-D-glucopyransoyl)-4-methyl-3-[5-(4-fluorophenyl)-2- thienylmethyl]benzene hemihydrate | Feb 26, 2029 | Janssen Pharms |
| Invokana | US7943788 | Glucopyranoside compound | Jul 14, 2027 | Janssen Pharms |
| Invokana | US8222219 | Glucopyranoside compound | Apr 11, 2025 | Janssen Pharms |
| Invokana | US8513202 | Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate | Dec 03, 2027 | Janssen Pharms |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳